WO2001029193A3 - Cell constructs that are suitable for immunotherapy, the production and the use thereof - Google Patents

Cell constructs that are suitable for immunotherapy, the production and the use thereof Download PDF

Info

Publication number
WO2001029193A3
WO2001029193A3 PCT/EP2000/010340 EP0010340W WO0129193A3 WO 2001029193 A3 WO2001029193 A3 WO 2001029193A3 EP 0010340 W EP0010340 W EP 0010340W WO 0129193 A3 WO0129193 A3 WO 0129193A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
production
cell constructs
constructs
cell
Prior art date
Application number
PCT/EP2000/010340
Other languages
German (de)
French (fr)
Other versions
WO2001029193A2 (en
Inventor
Peter Leskovar
Original Assignee
Peter Leskovar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19951072A external-priority patent/DE19951072A1/en
Priority claimed from DE10016846A external-priority patent/DE10016846A1/en
Application filed by Peter Leskovar filed Critical Peter Leskovar
Priority to AU11419/01A priority Critical patent/AU1141901A/en
Priority to EP00972821A priority patent/EP1226235A2/en
Publication of WO2001029193A2 publication Critical patent/WO2001029193A2/en
Publication of WO2001029193A3 publication Critical patent/WO2001029193A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
    • C12Y117/03—Oxidoreductases acting on CH or CH2 groups (1.17) with oxygen as acceptor (1.17.3)
    • C12Y117/03002—Xanthine oxidase (1.17.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to cell constructs and to methods for producing the same and to their use for the treatment of diseases that are caused by undesirable activated T cells.
PCT/EP2000/010340 1999-10-22 2000-10-20 Cell constructs that are suitable for immunotherapy, the production and the use thereof WO2001029193A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU11419/01A AU1141901A (en) 1999-10-22 2000-10-20 Cell constructs that are suitable for immunotherapy, the production and the use thereof
EP00972821A EP1226235A2 (en) 1999-10-22 2000-10-20 Cell constructs that are suitable for immunotherapy, the production and the use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19951072A DE19951072A1 (en) 1999-10-22 1999-10-22 New cell constructs from activated T-cells of patients useful as a medicament
DE19951072.5 1999-10-22
DE10016846.9 2000-04-05
DE10016846A DE10016846A1 (en) 2000-04-05 2000-04-05 New cell constructs from activated T-cells of patients useful as a medicament

Publications (2)

Publication Number Publication Date
WO2001029193A2 WO2001029193A2 (en) 2001-04-26
WO2001029193A3 true WO2001029193A3 (en) 2002-04-25

Family

ID=26005188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010340 WO2001029193A2 (en) 1999-10-22 2000-10-20 Cell constructs that are suitable for immunotherapy, the production and the use thereof

Country Status (3)

Country Link
EP (1) EP1226235A2 (en)
AU (1) AU1141901A (en)
WO (1) WO2001029193A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115927192A (en) * 2022-08-10 2023-04-07 浙江康佰裕生物科技有限公司 Preparation and application of novel universal CAR-T cell

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361908A2 (en) * 1988-09-28 1990-04-04 Ideon Corporation Combination enzyme immunotherapeutics
US5310541A (en) * 1992-08-27 1994-05-10 Montgomery Robert E Antimicrobial rawhide animal chew containing an oxidoreductase and oxidoreductase substrate
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids
WO2000012112A2 (en) * 1998-08-28 2000-03-09 The University Of Bath Treatment of lesions with xanthine oxidoreductase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4375293A (en) * 1992-05-13 1993-12-13 Beth Israel Hospital Association, The Targeted activated species cytotoxicity
AU5436796A (en) * 1995-03-31 1996-10-16 Catherine Bruyns Dendritic-like cell/tumor cell hybrids and hybridomas for in ducing an anti-tumor response
EP1168924A4 (en) * 1999-03-31 2002-09-04 Univ Pittsburgh In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361908A2 (en) * 1988-09-28 1990-04-04 Ideon Corporation Combination enzyme immunotherapeutics
US5310541A (en) * 1992-08-27 1994-05-10 Montgomery Robert E Antimicrobial rawhide animal chew containing an oxidoreductase and oxidoreductase substrate
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids
WO2000012112A2 (en) * 1998-08-28 2000-03-09 The University Of Bath Treatment of lesions with xanthine oxidoreductase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOGDAN CH ET AL: "Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity.", CURRENT OPINION IN IMMUNOLOGY., vol. 12, no. 1, February 2000 (2000-02-01), pages 64 - 76, XP001002146 *
PAHLAVANI M A & HARRIS M D: "Effect of in vitro generation of oxygen free radicals on T cell function in young and old rats.", FREE RADICAL BIOLOGY & MEDICINE, vol. 25, no. 8, 15 November 1998 (1998-11-15), pages 903 - 913, XP001002196 *

Also Published As

Publication number Publication date
AU1141901A (en) 2001-04-30
WO2001029193A2 (en) 2001-04-26
EP1226235A2 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
WO2005063971A3 (en) Definitive endoderm
WO2002028905A3 (en) Human anti-cd40 antibodies
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
AU2003283839A1 (en) Heteropolyacid and/or its salt supported catalyst, production process of the catalyst and production process of compound using the catalyst
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
WO2001021766A3 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2005113752A3 (en) Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
WO2000066528A3 (en) Quinones for treatment of diseases
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
AU2003300324A1 (en) Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
WO2002030870A3 (en) Substituted c-cyclohexylmethylamine derivatives
WO2001049651A3 (en) Aminomethyl-phenyl-cyclohexanone derivatives
WO2001029193A3 (en) Cell constructs that are suitable for immunotherapy, the production and the use thereof
WO2005094355A3 (en) Methods for altering protein production rates
WO2002022848A3 (en) Compositions comprising mixtures of human cytokines and methods of producing the same
WO2005012498A3 (en) Production of porphyrins
WO2003073988A3 (en) Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003062197A3 (en) Nek2 inhibitors
WO2004026895A3 (en) Gd2 ligands
WO2004078714A3 (en) Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazouinoxalines and heterocyclic-substituted imidazopyrazines
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
WO2004037278A3 (en) Delocalization molecules and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000972821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000972821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10111347

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP